- Home
- AUST vs ELEV Comparison
AUST vs ELEV Comparison
Compare AUST & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUST
- ELEV
- Stock Information
- Founded
- AUST 2020
- ELEV 2019
- Country
- AUST Canada
- ELEV United States
- Employees
- AUST N/A
- ELEV N/A
- Industry
- AUST
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- AUST
- ELEV Health Care
- Exchange
- AUST Nasdaq
- ELEV Nasdaq
- Market Cap
- AUST 39.0M
- ELEV 34.0M
- IPO Year
- AUST 2022
- ELEV 2021
- Fundamental
- Price
- AUST $1.78
- ELEV $0.58
- Analyst Decision
- AUST
- ELEV Strong Buy
- Analyst Count
- AUST 0
- ELEV 5
- Target Price
- AUST N/A
- ELEV $7.80
- AVG Volume (30 Days)
- AUST 436.2K
- ELEV 838.0K
- Earning Date
- AUST 11-06-2024
- ELEV 11-06-2024
- Dividend Yield
- AUST N/A
- ELEV N/A
- EPS Growth
- AUST N/A
- ELEV N/A
- EPS
- AUST N/A
- ELEV N/A
- Revenue
- AUST N/A
- ELEV N/A
- Revenue This Year
- AUST N/A
- ELEV N/A
- Revenue Next Year
- AUST N/A
- ELEV N/A
- P/E Ratio
- AUST N/A
- ELEV N/A
- Revenue Growth
- AUST N/A
- ELEV N/A
- 52 Week Low
- AUST $0.62
- ELEV $0.42
- 52 Week High
- AUST $3.19
- ELEV $5.83
- Technical
- Relative Strength Index (RSI)
- AUST 41.88
- ELEV 51.57
- Support Level
- AUST $2.23
- ELEV $0.60
- Resistance Level
- AUST $2.42
- ELEV $0.70
- Average True Range (ATR)
- AUST 0.35
- ELEV 0.05
- MACD
- AUST -0.14
- ELEV 0.01
- Stochastic Oscillator
- AUST 1.05
- ELEV 48.09
About AUST Austin Gold Corp.
Austin Gold Corp is a gold exploration and development company focused on gold targets and making district-scale gold discoveries in Nevada. Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Fourmile Basin in Nye County.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.